Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

BACKGROUND: Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Zrzavy, Tobias, Daniels, Esther, Stuka, Niklas, Weber, Dennis, Winkelmann, Alexander, Rauschka, Helmut, Hecker, Michael, Aboulenein-Djamshidian, Fahmy, Meister, Stefanie, Leutmezer, Fritz, Berger, Thomas, Bsteh, Gabriel, Zettl, Uwe Klaus, Rommer, Paulus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323410/
https://www.ncbi.nlm.nih.gov/pubmed/34377385
http://dx.doi.org/10.1177/20406223211024366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323410/
https://www.ncbi.nlm.nih.gov/pubmed/34377385
http://dx.doi.org/10.1177/20406223211024366

Ejemplares similares